Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer
NCT07121322Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dornase alfa in germ cell tumor (GCT), sponsored by National Cancer Institute. Started Jul 2025; status: recruiting.
02
Drugs
dornase alfa
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT07121322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121322.